ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR

A sudden, possibly drug-related death has overshadowed Turning Point Therapeutics’ update on repotrectinib in non-small cell lung cancer (NSCLC). More than four-fifths of patients responded to the tyrosine kinase inhibitor (TKI), but shares in Turning Point fell 10% amid worries about the death.